Regenerex PHARMA, Inc. (RGPX) intrinsic value & 10-year financials
Regenerex PHARMA, Inc. (RGPX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -31.9%
- ROIC (10-yr avg)
- 23.4%
- Free cash flow (FY2025)
- —
RGPX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$2.5M | — | — | — | 48.6% |
| FY2024 | — | -$3.5M | — | — | — | 110.9% |
| FY2023 | — | -$137.3K | — | — | — | 13.0% |
| FY2022 | — | -$195.6K | — | — | — | 21.5% |
| FY2021 | $1.8K | $353.8K | — | — | -17252.5% | -53.7% |
| FY2020 | $2.6K | -$111.6K | — | — | -2952.6% | 26.2% |
| FY2019 | — | -$93.6K | — | — | — | 27.1% |
| FY2018 | — | -$49.7K | — | — | — | 16.5% |
| FY2017 | — | -$2.6K | — | — | — | 0.9% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
REGENEREX PHARMA, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
REGENEREX PHARMA, INC. has earned high returns on invested capital, averaging 23.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
REGENEREX PHARMA, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, REGENEREX PHARMA, INC. is modeled at -31.9% normalized earnings growth with a 5.1% bond-yield adjustment.